CRL Stock News & Catalysts

FEATURED

Charles River Laboratories to Acquire Frontage’s Bioanalysis and DMPK Businesses

New

– Strengthens Charles River's Bioanalysis and DMPK Capabilities to Support Clients Across the Drug Development Lifecycle – – Advances Pathway to Purpose Strategy and Enhances Long-Term Growth and Value Creation

Summary

Nov 9, 2026, 6:10 AM ·Business Wire

RECENT

Charles River Laboratories Announces Third-Quarter 2026 Results

Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the third quarter ended September 26, 2026. Key Highlights Reports third-quarter revenue of $982.7 million, GAAP earnings

Nov 4, 2026, 7:00 AM ·Business Wire

Charles River Leverages Virtual Control Groups in GLP Studies

Collaboration highlights ongoing commitment to industry modernization and the highest animal welfare standards Charles River Laboratories International, Inc. (NYSE:CRL) today announced that its Virtual Control Group

Oct 27, 2026, 8:00 AM ·Business Wire

Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment

Joint research effort seeks to improve abuse potential assessment tools to support drug development and public health decision-making Charles River Laboratories International, Inc. (NYSE:CRL) today announced a

Oct 22, 2026, 4:30 PM ·Business Wire

Charles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine Development

Collaboration leverages next-generation sequencing (NGS) services to advance development and commercialization of an off-the-shelf therapy for osteoarthritis and future programs Charles River Laboratories

Oct 13, 2026, 8:00 AM ·Business Wire

Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call

Charles River Laboratories International, Inc. (NYSE:CRL) will release third-quarter 2026 financial results on Wednesday, November 4th, before the market opens. A conference call has been scheduled to discuss this

Oct 9, 2026, 8:00 AM ·Business Wire

Charles River and Autolomous Partner to Transform Laboratory Execution Systems

Partnership reinforces continued investment in digitization, automation, and client-facing transparency Charles River Laboratories International, Inc. (NYSE:CRL) and Autolomous today announced the launch of Apollo

Oct 6, 2026, 8:00 AM ·Business Wire

Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day

– Outlines Pathway to Purpose Strategy to Modernize the Company, Strengthen Its Scientific Portfolio, and Enhance the Client Experience – – Issues Long-Term Financial Targets through 2030 – – Reaffirms 2026

Sep 24, 2026, 8:00 AM ·Business Wire

Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines

Charles River platform offers 40% reduction in cell bank production timeline, over the industry standard of 20 weeks Charles River Laboratories International, Inc. (NYSE:CRL) has introduced rapid cell banking

Sep 17, 2026, 8:00 AM ·Business Wire

Charles River Laboratories to Present at Morgan Stanley and Baird Conferences

Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at two upcoming investor conferences, including: Morgan Stanley 24th Annual Global Healthcare Conference on Monday,

Sep 11, 2026, 8:00 AM ·Business Wire

Charles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite

Enhanced automation delivers improved traceability and capacity, while increasing manufacturing efficiency Charles River Laboratories International, Inc. (NYSE:CRL) has successfully implemented its Endosafe®

Sep 8, 2026, 8:00 AM ·Business Wire

Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing

Collaboration leverages NGS technologies to accelerate high-quality vaccine development, support global regulatory readiness, and help reduce animal testing Charles River Laboratories International, Inc. (NYSE:CRL)

Aug 20, 2026, 8:00 AM ·Business Wire

Charles River Laboratories Announces Second-Quarter 2026 Results

Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the second quarter ended June 27, 2026. Key Highlights Reports second-quarter revenue of $1.00 billion, GAAP loss per share

Aug 5, 2026, 7:00 AM ·Business Wire

Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call

Charles River Laboratories International, Inc. (NYSE:CRL) will release second-quarter 2026 financial results on Wednesday, August 5th, before the market opens. A conference call has been scheduled to discuss this

Jul 15, 2026, 8:00 AM ·Business Wire

Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches

Collaboration aligns with Charles River’s strategic commitment to building deeper client relationships and accelerating development with alternative methods Charles River Laboratories International, Inc. (NYSE:CRL)

Jul 13, 2026, 8:00 AM ·Business Wire

Charles River Laboratories International, Inc. CRL · News